Cancer screening in patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 33, Issue 1, 2006, Pages 45-49

  Bernatsky, Sasha R ^a,e   Cooper, Glinda S ^b   Mill, Chris ^a   Ramsey Goldman, Rosalind ^c   Clarke, Ann E ^d   Pineau, Christian A ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Division of Clinical Immunology/Allergy   (Canada)

^e McGill University Health Centre ^*  (Canada)

Author keywords

Cancer screening; Malignancy; Systemic lupus erythematosus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANADA; CANCER SCREENING; CAUCASIAN; CLINICAL PRACTICE; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; OCCULT BLOOD TEST; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CANCER;

ADULT; AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 30144435238     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bernatsky S, Boivin J-F, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus (SLE). Arthritis and Rheumatism 2005;52:1481-90.
2. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
3. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982;25:1271-7.
4. Canadian Task Force on the Periodic Health Examination: Canadian Guide to Clinical Preventive Health Care. Ottawa: Communication Group; 1994;797-809.
5. Colorectal cancer screening: Recommendation statement from the Canadian Task Force on Preventive Health Care. Can Med Assoc J 2001;165:206-8.
6. ACOG Practice Bulletin Number 45, August 2003: Committee on Practice Bulletins-Gynecology. Cervical Cytology Screening. Obstet Gynecol 2003;102:417-27.
7. Statistics Canada. Health Indicators. 82-221-XIE. Ottawa; 2001.
8. Mandelson MT, Curry SJ, Anderson LA, et al. Colorectal cancer screening participation by older women. Am J Prev Med 2000;19:149-54.
9. Madlensky L, McLaughlin J, Goel V. A comparison of self-reported colorectal cancer screening with medical records. Cancer Epidemiol Biomarkers Prev 2003;12:656-9.
10. Dhar J, Kmak D, Bhan R, Pishorodi L, Ager J, Sokol R. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol 2001;82:4-6.
11. Blumenfeld Z, Lorber M, Yoffe N, Scharf Y. Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 1994;3:59-61.
12. Bateman H, Yazici Y, Leff L, Peterson M, Paget SA. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000;9:542-4.
13. Nyberg G, Eriksson O, Westberg N. Increased incidence of cervical atypia in women with SLE treated with chemotherapy. Arthritis Rheum 1981;24:648-50.
14. Bernatsky S, Ramsey-Goldman R, Gordon C, et al. Factors associated with abnormal pap results in systemic lupus erythematosus (SLE). Rheumatology Oxford 2004;43:1386-9.
15. Sambamoorthi U, McAlpine DD. Racial, ethnic, socioeconomic, and access disparities in the use of preventive services among women. Prev Med 2003;37:475-84.
16. Bernatsky S, Pineau C, Joseph L, Clarke A. Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort. J Rheumatol 2003;30:1756-60.
17. Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. Version 1.0. IARC CancerBase No. 5. Lyon: IARC Press; 2001.
18. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. Can Med Assoc J 1997;157:408-6.
19. Hutchison B, Woodward C, Norman G, Abelson J, Brown J. Provision of preventive care to unannounced standardized patients. Can Med Assoc J 1998;158:185-93.
20. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA 2002;287:1269-76.
21. Ramsey S, Cheadle A, Neighbor W, et al. Relative impact of patient and clinic factors on adherence to primary care preventive service guidelines: an exploratory study. Med Care 2001;39:979-89.
22. Solomon DH, Karlson EW, Curham G. Cardiovascular care and cancer screenings in women with and without rheumatoid arthritis. Arthritis Rheum 2004;51:429-32.
23. Cibere J, Sibley S, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001;10:394-400.
24. Bootsma H, Derksen R, Jaegers S, et al. Usefulness of the SLICC/ACR Damage Index in patients with systemic lupus erythematosus [abstract]. Arthritis Rheum 1997;40 Suppl:S160.
25. Strand V, Gladman DD, Isenberg DA, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490-7.